13.08.2018
Formycon AG DE000A1EWVY8
DGAP-News: Formycon AG: Formycon Appoints Development and Production Expert Thomas Siklosi to the Advisory Board
DGAP-News: Formycon AG / Key word(s): Change of Personnel/Strategic Company
Decision
Formycon AG: Formycon Appoints Development and Production Expert Thomas
Siklosi to the Advisory Board
13.08.2018 / 08:00
The issuer is solely responsible for the content of this announcement.
---------------------------------------------------------------------------
Press Release // August 13, 2018
Formycon Appoints Development and Production Expert Thomas Siklosi to the
Advisory Board
- Renowned biotech manager to advise Formycon in future
- Advisory Board now numbers four highly regarded experts
Munich - The biosimilars company Formycon (ISIN: DE000A1EWVY8/ WKN: A1EWVY)
is appointing Thomas Siklosi, a former board member of Rentschler Biopharma
SE, to its Advisory Board. Siklosi is a renowned biotech manager and expert
in the development and production of biologics and biosimilars with 34 years
of professional experience in this field.
Thomas Siklosi studied chemistry at the Academy of Applied Sciences in Isny.
He completed his thesis with distinction at the Institute of Radiochemistry
at the Technical University of Munich. He gained his early professional
experience in the field of biotechnology at Boehringer Mannheim in the
laboratory led by Prof. Hans Ulrich Bergmeyer in Tutzing.
In 1984, he moved to the biotech pioneer Rentschler Arzneimittel in Laupheim
and held various roles in the development and production of interferons,
later being responsible at Rentschler Biotechnologie, a contract development
and manufacturing organization (CDMO), for the provision of
biopharmaceutical substances. In cooperation with a leading generic
manufacturer, he was responsible as project manager for the technical
development of the complex glycoprotein erythropoetin, which received
approval as the first epoetin-alfa biosimilar in the EU in the fall of 2007.
In September 2012, Siklosi was appointed to the Board of Management at
Rentschler Biopharma SE. As Chief Operating Officer, he was responsible for
the Development, GMP Production, Technology, and Quality departments.
Siklosi is a Member of the University Council of Biberach University and
owns numerous patents in the field of biotechnology.
Dr. Carsten Brockmeyer, board member and CEO of Formycon, said of Siklosi's
appointment: "I'm delighted that we have been able to bring on board Thomas
Siklosi, one of the world's most experienced biotech managers. As a man who
has been involved with biotechnology right from the start, he has managed
numerous biotechnology drugs and biosimilars from cell line development to
market maturity over the course of his career. With his many years of
in-depth experience in the management of major development and production
facilities, Mr. Siklosi will be advising and supporting Formycon AG on its
ambitious future projects."
Alongside Mr. Thomas Siklosi, the Advisory Board is also made up of Prof.
Johannes Buchner, Dr. Bernhard Hampl and Dr. Gerhard Schaefer.
About Formycon:
Formycon is a leading, independent developer of high-quality follow-on
products for biopharmaceutical medicines known as biosimilars. The company
focuses on treatments in ophthalmology, immunology and on other key chronic
diseases, covering the entire value chain from technical development to the
clinical phase III as well as the preparation of dossiers for marketing
approval. With its biosimilars, Formycon is making a major contribution
towards providing as many patients as possible with access to vital and
affordable medicines. Formycon currently has four biosimilars in
development.
About Biosimilars:
Since their introduction in the 1980s, biopharmaceuticals have
revolutionized the treatment of serious diseases such as cancer, diabetes,
rheumatoid arthritis, multiple sclerosis and eye diseases. In the coming
years, many of these biotech drugs will lose their patent protection - and
by 2020, medications with revenues of more than USD 100 billion will be off
patent. Biosimilars are follow-on versions of biopharmaceuticals, for which
exclusivity has expired. They are approved via stringent regulatory pathways
in highly regulated markets (such as EU, US, Japan, Canada, Australia) based
on proven similarity of the biosimilar with the originator biopharmaceutical
reference product. While the global market for biosimilars is currently more
than USD 5.0 billion, industry experts expect this figure to grow up to USD
30 billion by the year 2025.
Contact:
Thorsten Schüller
Corporate Communications and Investor Relations
Formycon AG
Fraunhoferstr. 15
82152 Martinsried/Planegg/Germany
phone +49 (0) 89 - 86 46 67 150
fax + 49 (0) 89 - 86 46 67 110
[email protected] // www.formycon.com
Disclaimer:
This press release may contain forward-looking statements and information
which are based on our current expectations and certain assumptions. Various
known and unknown risks, uncertainties and other factors could lead to
material differences between the actual future results, financial situation,
performance of the company, development of the products and the estimates
given here.
Such known and unknown risks and uncertainties comprise, among others, the
research and development, the regulatory approval process, the timing of the
actions of regulatory bodies and other governmental authorities, clinical
results, changes in laws and regulations, product quality, patient safety,
patent litigation, contractual risks and dependencies from third parties.
With respect to pipeline products, Formycon AG does not provide any
representation, warranties or any other guarantees that the products will
receive the necessary regulatory approvals or that they will prove to be
commercially exploitable and/or successful.
Formycon AG assumes no obligation to update these forward-looking statements
or to correct them in case of developments which differ from those
anticipated.
This document neither constitutes an offer to sell nor a solicitation of an
offer to buy or subscribe for securities of Formycon AG. No public offering
of securities of Formycon AG will be made nor is a public offering intended.
This document and the information contained therein may not be distributed
in or into the United States of America, Canada, Australia, Japan or any
other jurisdictions, in which such offer or such solicitation would be
prohibited. This document does not constitute an offer for the sale of
securities in the United States.
---------------------------------------------------------------------------
13.08.2018 Dissemination of a Corporate News, transmitted by DGAP - a
service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
The DGAP Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Archive at www.dgap.de
---------------------------------------------------------------------------
Language: English
Company: Formycon AG
Fraunhoferstraße 15
82152 Planegg-Martinsried
Germany
Phone: 089 864667 100
Fax: 089 864667 110
Internet: www.formycon.com
ISIN: DE000A1EWVY8
WKN: A1EWVY
Indices: Scale 30
Listed: Regulated Unofficial Market in Berlin, Frankfurt (Scale),
Tradegate Exchange
End of News DGAP News Service
---------------------------------------------------------------------------
713289 13.08.2018
|
Weitere Ad-hoc und Unternehmensrelevante Mitteilungen zu
Formycon AG ISIN: DE000A1EWVY8 können Sie bei EQS abrufen
Biotechnologie , A1EWVY , FYB , XETR:FYB